Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.016
Neutral
RSI(14)
50.727
Neutral
STOCH(KDJ)(9,3,3)
71.167
Neutral
ATR(14)
0.078
Low Volatility
CCI(14)
25.346
Neutral
Williams %R
30.000
Buy
TRIX(12,20)
0.027
Sell
StochRSI(14)
10.814
Oversold
Search
Phio Pharmaceuticals Corp
PHIOAdd to Watchlist
1.050USD
0.0000.00%
Close 07-27 16:00（ET）Quotes delayed by 15 min
12.20MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
-2.78%
1 Month
+8.25%
6 Months
+1.94%
Year to Date
0.00%
1 Year
-61.68%
Key Figures
1.050Open
1.070High
881.00Volume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.01%Turnover Ratio
1.050Prev. Close
1.030Low
122.00Turnover
LossP/E Static
0.74P/B
0.00%Div Yield TTM
-70.87%ROA
4.19052wk High
-0.01Volume Ratio
-7.15MNet Profit
11.62MShares
-1.3874EPS TTM
0.83Beta
-76.36%ROE
0.81352wk Low
3.80%Amplitude
--Gross Margin
12.20MMarket Cap
1.51Reward/Risk
5.47%Risk Rate
TradingKey Stock Score of Phio Pharmaceuticals Corp
Currency: USD Updated: 2026-07-27Key Insights
Phio Pharmaceuticals Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 117 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.00.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Phio Pharmaceuticals Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Phio Pharmaceuticals Corp Highlights
StrengthsRisks
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Undervalued
The company’s latest PE is -0.76, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.10M shares, increasing 0.63% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
14.000
Target Price
+1246.15%
Upside Space
Phio Pharmaceuticals Corp News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
1
analysts
Buy
Current Rating
14.000
Target Price
+1246.15%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Phio Pharmaceuticals Corp
PHIO
1
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.070
Sell
MA10
1.038
Buy
MA20
1.026
Buy
MA50
1.056
Sell
MA100
1.135
Sell
MA200
1.246
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Phio Pharmaceuticals Corp Info
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Ticker SymbolPHIO
CompanyPhio Pharmaceuticals Corp
CEOBitterman (Robert J)
Websitehttps://phiopharma.com/
Shareholders
Related Instruments
+1.45%
+3.12%
-0.29%
+1.48%
+1.52%
+1.06%
+1.65%
+0.24%
+0.79%
+0.93%
0.00%
+0.66%
+4.52%
0.00%
0.00%
0.00%
0.00%
+0.11%
0.00%
+1.26%Popular Instruments
52608.700
+369.700 (+0.71%)
27828.200
-227.800 (-0.81%)
7418.300
-0.100 (-0.00%)
14720.000
-393.000 (-2.60%)
62431.000
-1374.000 (-2.15%)
6272.700
-38.600 (-0.61%)
80.870
-0.467 (-0.57%)
338.400
+1.490 (+0.44%)
194.680
-1.829 (-0.93%)
4026.070
-50.370 (-1.24%)
FAQs
What is the current price of Phio Pharmaceuticals Corp (PHIO)?
The current price of Phio Pharmaceuticals Corp (PHIO) is 1.04.
What is the symbol of Phio Pharmaceuticals Corp?
The ticker symbol of Phio Pharmaceuticals Corp is PHIO.
What is the 52-week high of Phio Pharmaceuticals Corp?
The 52-week high of Phio Pharmaceuticals Corp is 4.19.
What is the 52-week low of Phio Pharmaceuticals Corp?
The 52-week low of Phio Pharmaceuticals Corp is 0.81.
What is the market capitalization of Phio Pharmaceuticals Corp?
The market capitalization of Phio Pharmaceuticals Corp is 12.08M.
Is Phio Pharmaceuticals Corp (PHIO) currently rated as Buy, Hold, or Sell?
According to analysts, Phio Pharmaceuticals Corp (PHIO) has an overall rating of Buy, with a price target of 14.00.
What is the Earnings Per Share (EPS TTM) of Phio Pharmaceuticals Corp (PHIO)?
The Earnings Per Share (EPS TTM) of Phio Pharmaceuticals Corp (PHIO) is -1.45.